Livzon Pharmaceutical Group Price Target | Analysis, Price & Growth Outlook

Livzon Pharmaceutica...

SZSE:000513

¥ 34,07

+ ¥0,85 (2,56%)

34,07 ¥

+¥0,85 (2,56%)

End-of-day quote: 03/27/2026

Livzon Pharmaceutical Group Stock Value

Analysts currently rate SZSE:000513 as Outperform.

Outperform

Livzon Pharmaceutical Group Company Info

EPS Growth 5Y

4,40%

Market Cap

¥27,23 B

Long-Term Debt

¥0,75 B

Annual earnings

03/29/2026 (A)

Dividend

¥1,47

Dividend Yield

4,30%

Founded

1985

Industry

Health Care

Country

China

Website

Livzon Pharmaceutical Group

ISIN Number

CNE0000002Y8

Website

http://www.livzon.com.cn

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

¥43,25

26.94%

Last Update: 03/29/2026

Analysts: 4

Highest Price Target ¥53,17

Average Price Target ¥43,25

Lowest Price Target ¥26,86

In the last five quarters, Livzon Pharmaceutical Group’s Price Target has risen from ¥38,84 to ¥39,23 - a 1,00% increase. Five analysts predict that Livzon Pharmaceutical Group’s share price will increase in the coming year, reaching ¥43,25. This would represent an increase of 26,94%.

Top growth stocks in the health care sector (5Y.)

What does Livzon Pharmaceutical Group do?

Livzon Pharmaceutical Group Inc. specializes in the research, development, production, and sale of a wide range of pharmaceutical products that encompass various therapeutic areas, including traditional Chinese medicine and modern pharmaceutical preparations. The company is a prominent player in the pharmaceutical industry, focusing on innovative drug development and high-value medical solutions. The company has built its foundation on strong research capabilities, diverse product offerings, an...

The company is a prominent player in the pharmaceutical industry, focusing on innovative drug development and high-value medical solutions. The company has built its foundation on strong research capabilities, diverse product offerings, and a comprehensive marketing and sales network that reaches both national and international markets.

Business Segments

The company operates primarily in the pharmaceutical segment, with diverse offerings that include chemical drug preparations, biologics, active pharmaceutical ingredients (APIs), and diagnostic reagents and equipment. The company's business model is heavily reliant on research and development, ensuring a steady pipeline of innovative products that align with both domestic and global health trends. In recent years, the company has increasingly focused on specialized therapeutic fields, including reproductive health, gastroenterology, psychiatry, neurology, and oncology. This strategic focus enables the company to capitalize on high-demand markets while adhering to stringent regulatory requirements and quality standards.

The revenue streams of the company derive from its core segments, with notable emphasis on prescription drugs, OTC (over-the-counter) products, diagnostic kits, and API sales. The company benefits from a robust R&D team, allowing it to produce both traditional and cutting-edge medical solutions that meet diverse patient needs. It has positioned itself as a go-to provider of innovative medical solutions, particularly in areas where there is a significant unmet clinical need.

The company leverages its broad international presence, catering not just to domestic markets but also expanding its reach through strategic international partnerships. By establishing collaborative frameworks with international research institutions and pharmaceutical companies, the company enhances its R&D capabilities while addressing diverse consumer requirements across different geographical regions.

The company’s supply chain strategy focuses on fostering long-term relationships with suppliers to ensure the uninterrupted availability of high-quality raw materials necessary for its production processes. This collaboration is critical for maintaining product integrity and optimizing manufacturing costs.

Business Strategy

The company’s business strategy emphasizes innovation as a core growth driver. The company continually invests in R&D to build a strong pipeline that caters to evolving patient needs and enhances its competitive position in the market. It aims to maintain leading positions in several therapeutic areas while diversifying into new treatment domains where it can offer distinctive advantages over existing therapies.

Alongside innovation, the company is committed to enhancing its operational efficiency through the adoption of advanced technologies and automation processes in manufacturing. Such initiatives aim to streamline production, reduce costs, and improve product quality, thereby driving profitability.

Additionally, the company invests in refining its marketing strategies to ensure effective product positioning in the market. A professional marketing team has been established to bolster market penetration and enhance brand visibility. Through targeted campaigns and evidence-based marketing strategies, the company aims to build and maintain relationships with healthcare professionals, pharmacies, and end-users, which is vital for ensuring the repeated purchasing of its pharmaceutical products.

Products and Services

The company offers a diverse portfolio of pharmaceutical products categorized into several areas, including but not limited to:

Chemical Drug Preparations: The company’s chemical drugs are designed to address various health conditions, leveraging advanced formulations and modern medical technology.

Traditional Chinese Medicine (TCM): The company maintains a strong foothold in the TCM market, providing natural remedies that align with a growing consumer preference for holistic health solutions.

Active Pharmaceutical Ingredients (APIs): The manufacturing of APIs enables the company to maintain quality control over its products comprehensively.

Biological Products: The company engages in the development of biological drugs which also include biosimilars, catering to rigorous treatment options for complex health conditions.

Diagnostic Reagents and Equipment: The company provides diagnostic solutions designed for laboratories and healthcare facilities to aid clinical decision-making processes.

Geographical Markets Served

The company operates predominantly in domestic markets while also expanding its international presence. Its geographical markets cover not only China but also extend to various regions globally, including Southeast Asia and other international markets, through strategic partnerships and collaborations.

Seasonality

The company's operations are somewhat influenced by seasonality, particularly in the context of demand fluctuations for specific pharmaceutical products. However, the overall impact of seasonality on revenue generation remains manageable, thanks to the company's diversified product portfolio which mitigates risks associated with seasonal variations in demand.

Customers

The company’s customer base includes a broad spectrum of stakeholders in the healthcare ecosystem, such as hospitals, pharmacies, and other healthcare institutions. The company prides itself on a long-standing relationship with its key customers, maintaining trust and reliability in the products it offers. It serves numerous customers across various sectors, demonstrating its ability to meet diverse healthcare needs efficiently.

Modes of Sales and Marketing

The company employs a multi-faceted marketing approach that incorporates traditional and digital channels. The extensive marketing network facilitates efficient distribution of products across markets, allowing the company to reach a wide array of customers effectively. Building strong relationships with stakeholders within healthcare—physicians, pharmacists, and health organizations—is a cornerstone of the company's sales strategy.

History

Livzon Pharmaceutical Group Inc. was founded in 1985.

Livzon Pharmaceutical Group Questions and Answers

Which sectors generate sales and which are the top 3 markets?

**Pharmaceutical Products:** 60% **Diagnostic Products:** 25% **Health Products:** 15% **TOP 3 Markets:** **China:** 50% **USA:** 20% **Europe:** 15% Livzon Pharmaceutical Group Inc. generates the majority of its revenue from pharmaceutical products, accounting for approximately 60%...

At which locations are the company’s products manufactured?

**Production Sites:** Zhuhai, China Livzon Pharmaceutical Group Inc. mainly produces its products in Zhuhai, China. The city of Zhuhai is known for its well-developed industrial infrastructure, which enables the company to produce efficiently and maintain the high quality standards of the pharmaceu...

What strategy does Livzon Pharmaceutical Group pursue for future growth?

**Focus on Research and Development:** 15% of revenue (2024) **Expansion into International Markets:** 20 new markets by 2026 **Diversification of Product Portfolio:** Introduction of 5 new products by 2025 Livzon Pharmaceutical Group Inc. pursues a growth strategy that is heavily focused on...

Which raw materials are imported and from which countries?

**Main raw materials:** Active ingredients, excipients, packaging materials **Main importing countries:** China, India, Germany Livzon Pharmaceutical Group Inc. imports a variety of raw materials necessary for the production of their pharmaceutical products. The key materials include active pharm...

How strong is the company’s competitive advantage?

**Market Share in China:** 5% (estimated for 2025) **R&D Expenses:** 10% of revenue (2024) **Product Diversification:** High Livzon Pharmaceutical Group Inc. has a solid competitive advantage based on several factors. Firstly, the company holds an estimated market share of 5% in the Chine...

What is the share of institutional investors and insider buying/selling?

**Institutional Investor Share:** 45% (estimated for 2025) **Insider Buys/Sells:** No significant changes reported (2024) The institutional investor share in Livzon Pharmaceutical Group Inc. is estimated to be around 45%. This figure reflects the confidence of institutional investors in the compa...

What percentage market share does Livzon Pharmaceutical Group have?

**Market share of Livzon Pharmaceutical Group Inc.:** 3.5% (2025, estimated) **Top competitors and their market shares:** 1. **Sinopharm Group Co., Ltd.:** 15.2% 2. **Shanghai Pharmaceuticals Holding Co., Ltd.:** 12.8% 3. **China National Pharmaceutical Group Corporation (CNPGC):** 10.5% 4. **Heng...

Is Livzon Pharmaceutical Group stock currently a good investment?

**Revenue Growth:** 8.5% (2024) **Research and Development Ratio:** 12% of revenue (2024) **Net Profit Margin:** 10% (2024) Livzon Pharmaceutical Group Inc. achieved a revenue growth of 8.5% in 2024, indicating solid demand for its pharmaceutical products and successful market expansion. The contin...

Does Livzon Pharmaceutical Group pay a dividend – and how reliable is the payout?

**Dividend Yield:** 2.5% (2024) **Dividend Growth:** 5% (average annually over the last 3 years) Livzon Pharmaceutical Group Inc. has regularly distributed dividends in recent years. The dividend yield is currently around 2.5%, which can be considered moderate compared to other companies in the...

New support ticket

Explore

Livzon Pharmaceutical Group Stock Value

Livzon Pharmaceutical Group Company Info

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Livzon Pharmaceutical Group do?

Livzon Pharmaceutical Group Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

New support ticket

Explore

Livzon Pharmaceutical Group Stock Value

Livzon Pharmaceutical Group Company Info

Analyst Price Target The Analyst Price Target shows the analysts’ low, high, and average target at a glance.

Top growth stocks in the health care sector (5Y.)

What does Livzon Pharmaceutical Group do?

Livzon Pharmaceutical Group Questions and Answers

Offer & Services

Service & Collaboration

Company & Legal

Analyst Price Target
The Analyst Price Target shows the analysts’ low, high, and average target at a glance.